IPF DRUGS APPROVED BY US FDA

Oct 15, 2014, 15:13 PM
announcement_icn_45
The US FDA approves Esbriet® (pirfenidone) and Ofev® (nintedanib) for the treatment of idiopathic pulmonary fibrosis. Both drugs recently received the FDA’s “breakthrough therapy” designation, which accelerated the FDA review process. Esbriet is manufactured by InterMune, Inc. and Ofev is distributed by Boehringer Ingelheim Pharmaceuticals, Inc.

Read Ofev Now Available in US

Read PFF News Release

Read FDA News Release for Esbriet

Read FDA News Release for Ofev
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >